Metabolic and Molecular Mechanisms of NAFLD/NASH

NAFLD/NASH 的代谢和分子机制

• 批准号: 10682156
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.92万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-15 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10682156
• 关键词: Alberta province; Antidiabetic Drugs; Area; Biological Process; Biology; Biotechnology; Canada; Career Mobility; Clinical; Collaborations; Communities; Data; Dedications; Development; Diabetes Mellitus; Diagnostic; Disease; Education; Educational workshop; Event; Fibrosis; Fostering; Genetic; Goals; Growth; Hepatic; Hepatocyte; Histologic; Industry; Inflammation; Inflammatory; Insulin Resistance; Joints; Knowledge; Learning; Life Style Modification; Lipids; Liver; Liver Fibrosis; Liver diseases; Lobular; Mediator; Medical; Metabolic; Metabolic Diseases; Metabolic syndrome; Methodology; Molecular; Morbidity - disease rate; Obesity; Organ; Outcome; Participant; Pathogenesis; Pathogenicity; Pathway interactions; Pharmacologic Substance; Progressive Disease; Regulation; Research; Research Personnel; Resolution; Role; Scientist; Steatohepatitis; Testing; Therapeutic Agents; Therapeutic Intervention; Thinking; Update; Weight-Loss Drugs; Work; career; clinical practice; design; improved; liver inflammation; liver transplantation; mortality; multidisciplinary; next generation; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; posters; programs; symposium

ABSTRACT Support is requested for a Keystone Symposia conference entitled Metabolic and Molecular Mechanisms of NAFLD/NASH, organized by Drs. James Trevaskis, Jacquelyn Maher and Quentin Anstee. The conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023. Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) represents the hepatic manifestation of the metabolic syndrome and is emerging as a key driver of morbidity and mortality, particularly when present in the context of severe liver fibrosis. The histological hallmarks of NASH including steatosis, lobular inflammation and hepatocyte ballooning are well-characterized; however, while it is widely recognized that NASH is a progressive disease, the pathogenic and molecular mechanisms that initiate and drive NASH remain largely unknown. Therefore, this conference was designed to bring together a broad group of scientific and clinical researchers to highlight and discuss the current evidence exploring the key biological processes involved in NASH and liver fibrosis. This conference program will cover topics such as insulin resistance, hepatocyte lipid management/lipotoxicity and inflammation in the context of steatosis and NASH. Furthermore, advances in our understanding of the molecular and genetic regulation of NAFLD/NASH and the progression to liver fibrosis will also be highlighted. Finally, as NASH is an unmet medical need, this program will integrate the earlier fundamental biology discussion with updates on clinical progress of therapeutic agents, and combinations of agents, for the treatment of NASH and liver fibrosis. Finally, this conference will be held jointly with Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies. The joint conference will focus on the key cellular drivers and mediators of fibrosis in organs beyond the liver and allows for cross-functional discussion and deeper understanding of pathobiology of fibrotic disease. Participants from both conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster sessions.

抽象的 请求支持Keystone研讨会会议，标题为“代谢和分子机制” Nafld/Nash，由Drs组织。 James Trevaskis，Jacquelyn Maher和Quentin Anstee。会议 将于2023年3月19日至23日在加拿大艾伯塔省的班夫举行。 非酒精性脂肪肝病（NAFLD）和脂肪性肝炎（NASH）代表肝表现 代谢综合征，正在成为发病和死亡率的关键驱动力，尤其是在 严重的肝纤维化的背景。 NASH的组织学标志，包括脂肪变性，小叶 炎症和肝细胞气球的表征良好；但是，虽然广泛认识到 纳什是一种进行性疾病，是启动和驱动纳什的致病和分子机制 在很大程度上未知。因此，该会议旨在汇集一大批科学 和临床研究人员，以突出和讨论探讨关键生物学过程的当前证据 参与NASH和肝纤维化。该会议计划将涵盖诸如胰岛素抵抗等主题， 在脂肪变性和纳什的背景下，肝细胞脂质管理/脂肪毒性和炎症。此外， 我们对NAFLD/NASH的分子和遗传调节的理解和进展的进步 肝纤维化也将突出显示。最后，由于纳什是未满足的医疗需求，该程序将集成 早期的基本生物学讨论，有关治疗剂的临床进展的最新信息，以及 剂的组合，用于治疗NASH和肝纤维化。最后，这次会议将共同举行 具有纤维化发病机理和分辨率：从机制到疗法。联合会议将重点关注 肝脏以外器官中纤维化的关键细胞驱动因素和介体允许交叉功能 讨论和对纤维化疾病病理生物学的更深入了解。来自两个会议的参与者 将有机会通过共享的会议，进餐时间和晚间海报会议进行联网。